文献速递妇科

成人共病评估-27在子宫内膜癌中的临床应用

[Clinical application of adult comorbidity evaluation-27 in endometrial cancer].
PubMed 文献 · Zhonghua Fu Chan Ke Za Zhi · 2016-01-01

回顾性分析847例子宫内膜癌患者,采用成人共病评估-27(ACE-27)评估共病,Kaplan-Meier法分析生存,Cox模型分析预后与ACE-27、年龄、BMI及病理特征的关系。ACE-27评分越高总生存时间逐渐缩短,评分3分较0分死亡风险增加(多因素OR=2.40,P=0.000)。

要点

  • ACE-27评分0、1、2、3分者分别占36.7%、31.1%、15.6%、16.6%。
  • ACE-27评分越高,子宫内膜癌患者总生存时间逐渐缩短(χ2=19.003,P=0.000)。
  • 多因素分析中ACE-27评分3分较0分死亡风险增加(OR=2.40,P=0.000)。

核心结论

  • ACE-27可能成为子宫内膜癌患者预测治疗和预后的因素之一。
  • 应详细收集共病临床资料以评估预后和治疗方案。

研究设计与样本

  • 回顾性分析1985年1月至2015年12月天津医科大学总医院847例子宫内膜癌患者,均接受手术且术前未行放化疗,平均年龄57.6岁(范围25~85岁),平均随访59.0个月(范围2~312个月)。

主要发现

  • ACE-27评分0、1、2、3分者分别为311例(36.7%)、263例(31.1%)、132例(15.6%)、141例(16.6%)。
  • Kaplan-Meier分析显示ACE-27评分越高总生存时间逐渐缩短(χ2=19.003,P=0.000)。
  • BMI<25 kg/m2和BMI 25-<30 kg/m2、FIGOⅠ期、子宫内膜腺癌类型患者中,ACE-27评分越高总生存时间逐渐缩短(P<0.05);BMI≥30 kg/m2、FIGOⅡ-Ⅳ期和非子宫内膜腺癌类型患者中总生存时间差异无统计学意义(P>0.05)。
  • 单因素分析显示ACE-27评分3分较0分死亡风险增加(OR=2.53,P=0.000);年龄50-59、60-69、≥70岁,BMI 25-<30 kg/m2和≥30 kg/m2,G3,FIGOⅡ-Ⅳ期和非子宫内膜腺癌类型患者总生存时间较年龄<50岁、BMI<25 kg/m2、G1、FIGOⅠ期和子宫内膜腺癌类型显著缩短(均P<0.05)。
  • FIGOⅢ或Ⅳ期患者术后化疗或放疗率随ACE-27评分增加而降低,但差异无统计学意义(P>0.05)。

临床怎么用

  • 作者认为ACE-27可能成为子宫内膜癌患者预测治疗和预后的因素之一,并建议详细收集共病临床资料以评估预后和治疗方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the significant role of the clinical application of adult comorbidity evaluation-27 (ACE-27) in endometrial cancer (EC). Methods: A total of 847 EC patients were included during Jan. 1985 to Dec. 2015 from Tianjin Medical University General Hospital. The clinical data of the patients were collected and analyzed retrospectively. All of the patients were received operation with no chemotherapy and radiotherapy before operation. The average age was 57.6 years old (range from 25 to 85 years old). The average follow-up period was 59.0 months (range from 2 to 312 months). The comorbidity of the patients was evaluated by ACE-27. EC patients survival was analyzed by Kaplan-Meier survival curve. The relationship between the prognosis of EC and ACE-27, age, body mass index (BMI) , pathological characteristic were showed by Cox modeling. Results: (1) The patient number of score 0, 1, 2 and 3 of ACE-27 in EC patients were respectively 311 (36.7%), 263 (31.1%), 132 (15.6%) and 141 (16.6%) cases. (2) Kaplan-Meier survival curve analysis showed that overall survival time of EC patients was gradually decreased as increased score of ACE-27 (χ2=19.003, P=0.000) . In the patients of BMI<25 kg/m2 and BMI 25-<30 kg/m2, International Federation of Gynecology and Obstetrics (FIGO) stage Ⅰ, endometrial adenocarcinoma type and the overall survival time of those EC patients were gradually decreased as increased score of ACE-27 (P<0.05) . However, there was no statistically significant difference in overall survival time for patients with BMI ≥30 kg/m2, FIGO stage with Ⅱ-Ⅳand non-endometrial adenocarcinoma type (P>0.05). Per unvariate logistic modeling showed that the risk of death in score 3 of ACE-27 was increased compared with score 0 of ACE-27 (OR=2.53, P=0.000) . The overall survival time in EC patients with aged 50-59, 60-69 and ≥70 years old, BMI 25-<30 kg/m2 and ≥ 30 kg/m2, G3, FIGO stage Ⅱ-Ⅳ and non-endometrial adenocarcinoma type were significantly decreased compared with those aged <50 years old, BMI < 25 kg/m2, G1, FIGO stage Ⅰ and endometrial adenocarcinoma type (all P<0.05) . Further we found that postoperative chemotherapy or radiotherapy rate were decreased for EC patients with FIGO staging Ⅲ or Ⅳ as the increase of ACE-27 score, but there was no statistically significant difference (P>0.05). (3) Per multivariate logistic modeling showed that the risks of death in score 3 of ACE-27 was increased compared with score 0 of ACE-27 among age-adjusted, BMI, histological grade, FIGO stage and pathologic type (OR=2.40, P=0.000) . Per multivariate logistic modeling showed that, the overall survival time in EC patients with aged 60-69 and ≥70 years old, BMI 25-<30 kg/m2 and ≥30 kg/m2, FIGO stage Ⅲ-Ⅳ and non- endometrial adenocarcinoma type remain significantly decreased compared with those aged <50 years old, BMI<25 kg/m2, FIGO stage Ⅰ and endometrial adenocarcinoma type (P<0.05) , but there was no statistically significant difference in histological grade (P>0.05). Conclusions: ACE-27 may become one of the factors of predictive therapy and the prognosis for EC patients. The detailed clinical data of comorbidity should be collected to evaluate prognosis and therapy plan.

来源:Zhonghua Fu Chan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Tian WY, Wang YM, Yan Y, et al. [Clinical application of adult comorbidity evaluation-27 in endometrial cancer]. Zhonghua Fu Chan Ke Za Zhi. 2016. PMID: 27916063. doi:10.3760/cma.j.issn.0529-567X.2016.11.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。